Previous close | 2.6173 |
Open | 2.6100 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 2.5750 - 2.6400 |
52-week range | 2.4900 - 4.4700 |
Volume | |
Avg. volume | 33,444 |
Market cap | 648.455M |
Beta (5Y monthly) | 1.24 |
PE ratio (TTM) | ∞ |
EPS (TTM) | 0.0000 |
Earnings date | 10 May 2024 - 14 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
WELL and HEALWELL AI have launched the second-generation of WELL AI Decision Support (“WAIDS”), which now features advanced chronic disease screening for diseases like chronic kidney disease, hypertension, and diabetes, enabling patient risk stratification.The updated WAIDS tool identifies over one hundred diseases and delivers actionable clinical insights at the point of care, contributing to the management of chronic disease-related costs in Canada, which are estimated to be approximately $190
WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) ("WELL" or "the Company"), a company focused on positively impacting health outcomes by leveraging technology to empower healthcare providers and their patients globally, is pleased to announce it is collaborating with Microsoft to accelerate healthcare's digital transformation. This five-year agreement is set to accelerate the digital transformation of healthcare delivery across North America and beyond, integrating Microsoft Cloud and A
With its stock down 17% over the past three months, it is easy to disregard WELL Health Technologies (TSE:WELL). We...